

REMARKS

The Examiner required restriction of the claims of the application into six hundred and seventy two (672) different groups. In response, Applicants elect Group 11, claims 1, 2, 17, 18, and 6, drawn to a polypeptide having SEQ ID NO:11, with traverse. Applicants traverse on the grounds that the search and examination of at least the following groups, all of which are directed to some aspect of SEQ ID NO:11, is not unduly burdensome to the examiner: Group 53 (drawn to a polynucleotide encoding the polypeptide having SEQ ID NO:11), Group 95 (drawn to a transgenic organism comprising a polynucleotide encoding the polypeptide having SEQ ID NO:11), Group 137 (drawn to an antibody against a polypeptide having SEQ ID NO:11), Group 179 (drawn to a method for detecting a polynucleotide using a polynucleotide encoding a polypeptide encoding the polypeptide having SEQ ID NO:11), Group 221 (drawn to a method of treatment by administering a polypeptide having SEQ ID NO:11), and Group 641 (drawn to a method for assessing toxicity using a polynucleotide encoding the polypeptide having SEQ ID NO:11).

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Feb 26, 2007

By Michele M. Simkin

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5538
Facsimile: (202) 672-5399

Michele M. Simkin
Attorney for Applicants
Registration No. 34,717